Therefore, our study indicates that in addition to conventional targeting of transcriptional Wnt/β-catenin signaling [43], the metabolic factor SIRT1 may represent a new target for the development of novel therapeutics aimed at preventing SMG-induced bone loss or treating patients with osteoporosis. Here, SIRT1 is linked to osteoporosis.